Alkermes Emerges In 2024 With A Fresh Focus

CEO Richard Pops Says The Company Is Returning To Its CNS Routes

As a streamlined pharma business focused on neuroscience, having spun out its oncology programs, Alkermes is building its CNS presence and going “all in” with an early stage pipeline candidate for narcolepsy.  

Richard Pops, CEO of Alkermes
Richard Pops, CEO of Alkermes

Alkermes plc has undergone a transformation, shifting from a drug delivery and formulation company to an innovative pharma company. The group recently completed the spin-out of its oncology business and narrowed its focus to diseases of the central nervous system.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

More from Leadership